Started in 2007, ChemPartner’s biology and pharmacology department specializes in drug discovery services for several key bio-therapeutic areas, including oncology, cell biology, immunology, inflammation, neuroscience, and metabolic disorders. From target validation, HTS, hit-to-lead, lead optimization, and candidate selection to IND enabling studies, we are innovation driven and customer focused, providing a broad range of discovery services with expertise, experience, and commitment.
Our biology team is led by senior scientists with extensive discovery experience in the biopharmaceutical industry in the US and Europe. We pride ourselves on having numerous validated key discovery assays and assay panels for many different targets (e.g., extensive cancer cell panel of 800+, CRISPR, kinase/epigenetic/GPCR panels, hERG, and QPatch). Nurmerous in vivo models are routinely used and amendable to customization, such as patient-derived xenografts (PDXs), cancer cell-derived xenografts (CDXs), and syngeneic models, as well as many inflammation and autoimmune related modes (CIA, AIA, asthma, lung fibrosis, IBD, EAE), CNS-related (5XFAD mice), and metabolic disease-related (e.g., Ob/Ob, db/db mice) transgenic rodent models. We have an AAALAC approved, state-of-the-art animal housing and breeding facility at our sites in both Shanghai and Qidong.
Our highly experienced and communicative biologists provide strong intellectual input when working closely and flexibly with our clients. We provide customized designs or co-develop many of the needed in vitro and in vivo assays and disease models required to drive all discovery projects within a tight timeline. Furthermore, we are well-equipped with the latest technology platforms needed including Caliper, FLIPR, high content analysis, FACS, Luminex, in vivo imaging, Laborus, and QPatch.
Our well-coordinated, integrated services model means our medicinal chemist, DMPK, and bioanalytical scientist colleagues are all working together cohesively. We have efficiently and successfully delivered countless leads and clinical candidates with several of them currently in clinical trials.